# A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

> **NCT05381142** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Hot Flashes
- Healthy Volunteers

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05381142
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-23
- **Primary completion:** 2022-07-11
- **Final completion:** 2022-07-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05381142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05381142, "A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05381142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*